Trials / Unknown
UnknownNCT05156515
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to construct a noninvasive approach using 68Ga-THP-APN09 PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 68Ga-THP-APN09 | APN09, nanobody targeting PD-L1, labeled with PET radio-nuclide (68Ga) will be used as a molecular imaging tracer for PET/CT scan. |
Timeline
- Start date
- 2021-12-09
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2021-12-14
- Last updated
- 2023-03-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05156515. Inclusion in this directory is not an endorsement.